Proposal to widen access to imiglucerase for type 1 and type 3 Gaucher disease

Medicines

Consultation Closed

PHARMAC is seeking feedback on a proposal to widen access to imiglucerase from 1 September 2013.

In summary the proposal would result in

  • patients with Gaucher disease Type 3 having access to funded imiglucerase;
  • the maximum funded dose of imiglucerase being increased from 15 iu/kg per month to 30 iu/kg per month for children meeting certain criteria

Feedback sought

PHARMAC welcomes feedback on this proposal. To provide feedback, please submit it in writing by 5pm Wednesday, 10 July 2013 to:

Adrienne Martin
Therapeutic Group Manager
PHARMAC

E-mail: Adrienne.Martin@pharmac.govt.nz
Fax: 04 460 4995
Post: PO Box 10 254, Wellington 6143

All feedback received before the closing date will be considered by PHARMAC’s Board (or its delegate) prior to making a decision on this proposal.